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Abstract:  Control  of  flavonoid  derivatives  inhibitors  release  through  the  inhibition  of 
neuraminidase has been identified as a potential target for the treatment of H1N1 influenza 
disease. We have employed molecular dynamics  simulation  techniques to  optimize the 
2009 H1N1 influenza neuraminidase  X-ray  crystal  structure. Molecular docking of the 
compounds  revealed  the  possible  binding  mode.  Our  molecular  dynamics  simulations 
combined  with  the  solvated  interaction  energies  technique  was  applied  to  predict  the 
docking  models  of  the  inhibitors  in  the  binding  pocket  of  the  H1N1  influenza 
neuraminidase.  In  the  simulations,  the  correlation  of  the  predicted  and  experimental 
binding free energies of all 20 flavonoid derivatives inhibitors is satisfactory, as indicated 
by R
2 = 0.75. 
Keywords: molecular dynamics; H1N1; neuraminidase; molecular docking 
 
1. Introduction  
Since  March  2009,  a  new  strain  of  the  influenza  A  virus  (H1N1)  has  rapidly  spread  to  many 
countries from the initial outbreak in South America. In July 2009, the WHO (World Health Organization) 
declared that the spread of H1N1 influenza virus had become a serious global pandemic. Recently, the 
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H1N1 influenza associated reports state that several mutation strains of H1N1 influenza A viruses are 
resistant to oseltamivir and zanamivir [1–3]. Influenza viruses have been classified by the antigenic 
properties of two glycoproteins, sixteen hemagglutinin proteins and nine neuraminidase proteins [4,5]. 
The hemagglutinin proteins play a role as antigens binding to the sialic acid receptor on the host cell 
surface, which aids the entry of the virus [6]. The function of the neuraminidase antigen is to cleave 
the terminal linkage of the sialic acid receptor, which results in the release of the progeny virions from 
the infected host cells. In addition, neuraminidase may have a function as importer facilitating the early 
process of the infection of lung epithelial cells by the influenza virus [7]. Because of its essential role 
in  influenza  virus  replication  and  its  highly  conserved  active  sites,  neuraminidase  has  been  an 
attractive target for the development of novel anti-influenza drugs [8–14].  
In recent years, several flavonoids have been reported as showing anti-influenza virus activity by 
inhibiting  neuraminidase  [15–19].  Flavonoids  are  low  molecular  weight  compounds  that  are 
widespread in the plant kingdom. Those compounds have been shown to possess several biological 
effects in mammals [20–22]. In particular in vitro studies, scientists report that flavonoids may inhibit 
several  enzymes  related  to  the  cardiovascular  system  [23–27],  especially  inhibiting  the  Matrix 
Metalloproteinases  (MMPs)  [28].  Therefore,  using  flavonoids  as  antivirals  should  be  carefully 
considered  in  addition  to  these  other  proposed  activities.  In  general,  flavonoids  are  interesting 
molecules combining an aromatic nature with several hydrophilic groups. These aromatic interactions 
play  a  key  role  in  protein-protein  and  protein-ligand  interactions  [29–31].  The  hydrophilic  nature 
(hydroxyl (OH) functional group of flavonoids/water molecules) of the falvonoids shows that water 
displacement is key for determining ligand affinity [32–36].  
Scientists also report that the flavonoid derivatives can efficiently inhibit the activity of H1N1 
neuraminidase  [37].  To  reveal  the  inhibition  mechanism  of  flavonoid  derivatives  on  H1N1 
neuraminidase, a knowledge of the three-dimensional structure of H1N1 neuraminidase is indispensable. 
Since H1N1 neuraminidase structures have been determined by X-ray experiments [5,38], we chose 
the structure (PBD ID: 3NSS) as the target structure for these studies.  
In this study, the 20 flavonoid derivatives (2,3-dihydrobenzofuran and 5,7-dihydroxychromen-4-one 
backbones) and their experimental biological binding affinities [37,39] were chosen to simulate H1N1 
neuraminidase pharmacological activities; these inhibitors are listed in Table S1. The transfer function [40] 
(ΔGbind = −RT ln(IC50)) is used to transfer the experimental values (IC50 ) to the experimental binding 
free energies values; these experimental values are listed in Table S1. Molecular docking, molecular 
dynamics  simulations  (MD),  and  binding  free  energies  calculations  were  used  to  gain  further  
insight  into the binding interactions  between the 2009 H1N1 neuraminidase and the 20  flavonoid  
derivatives inhibitors. 
2. Results and Discussion  
2.1. Molecular Docking and MD Simulation  
The  20  flavonoid  derivatives  were  docked  into  the  H1N1  neuraminidase  structure.  Over  the  
10-ns MD trajectories of the H1N1 neuraminidase with tip3 water molecules and flavonoid derivatives, 
the overall structure of both complexes appeared to be equilibrated after 324 ps. Here, we show the Int. J. Mol. Sci. 2012, 13  4498 
 
RMSD profiles of 20 flavonoid derivatives (Figure 1) and the snapshot (Figure 2) of the complex 
system of the flavonoid derivatives 1. The RMSD values of 20 flavonoids stay within 4 Å. 
Figure 1. RMSD profiles of 20 flavonoid derivatives. 
 
Figure 2. The snapshot of the 2009 H1N1 neuraminidase of the inhibitor 1. 
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2.2. Key Residues of 2009 H1N1 Neuraminidase  
The study of these 20 compounds has revealed that the amino residues can frequently interact with 
flavonoid inhibitors in the H1N1 neuraminidase binding site, and that these residues are responsible for 
the  selectivity  of  flavonoid  inhibitors.  The  results  of  our  simulations  are  listed  in  Table  1  and  
Figure S1–S20. The inhibitors 1–3 and 14 (Table 1) belong to the 2,3-dihydrobenzofuran backbone 
inhibitors  and  the  others  belong  to  the  5,7-dihydroxychromen-4-one  backbone  inhibitors.  In  the  
2,3-dihydrobenzofuran backbone inhibitors (inhibitor 1–3 and 14), Asn295,Glu119, Glu277, Thr226, 
Trp179 can form hydrogen bonds in the 2009 H1N1 neuraminidase/flavonoids complex structures and 
Asn295 most frequently forms the hydrogen bonds. Only Tyr402 has non-bonding interactions with 
inhibitor 1 (Figure S1). In the 5,7-dihydroxychromen-4-one backbone inhibitors (inhibitor 4–13 and 
15–20),  Arg152,  Asn295,  Asn325,  Asn344,  Asp151,  Asp294,  Glu119,  Glu228,  Glu277,  Ser180, 
Ser247,  Ser366,  Ser367,  Thr226,  Trp179,  Tyr402  and  Val346  can  form  hydrogen  bonds  in  the 
complex structures and Glu228 most frequently forms the hydrogen bonds. Arg368, Ile223, Pro326 
and Trp179 have non-bonding interactions with the backbone inhibitors (Figure S7, 16 and 19). The 
overall results of our simulations suggest that Arg152, Asn295, Asn325, Asn344, Asp151, Asp295, 
Glu119, Glu228, Glu277, Ser180, Ser247, Ser366, Ser367, Thr226, Trp179, Tyr402 and Val346 can 
form hydrogen bonds between the 2009 H1N1 neuraminidase and flavonoid derivatives. Moreover, 
our simulations indicate that Arg368, Ile223, Pro326 and Trp179 have non-bonding interactions with 
these derivatives. The non-bonding interactions of the 2009 H1N1 neuraminidase/flavonoid complex 
structures only occurred in inhibitor 1, 7, 16 and 19 simulations. While six residues (Arg152, Asn295, 
Glu228, Glu277 Trp179 and Val346) more often formed the hydrogen bonds of the complex structures, 
Asn295 most frequently formed the hydrogen bonds.  
Table 1. Important results: Important residues of the 2009 H1N1 neuraminidase from the 
molecular docking and molecular dynamics (MD) simulations. 
Inhibitors   Hydrogen bonding–related residues   Non-bonding contact-related residues 
1(A)  Trp179, Thr226, Asn295  Tyr402 
2(A)  Glu277, Asn295  Null 
3(A)  Glu119, Asn295  Null 
4(B)  Glu119, Ser180, Glu228, Asp294, Val346  Null 
5(B)  Val346  Null 
6(B)  Arg152, Glu228, Glu277 Asn295   Null  
7(B)  Asn295  Trp179, Ile223 
8(B)  Glu119, Ser180, Glu228, Asp294, Val346  Null 
9(B)  Arg152, Glu228, Val346  Null 
10(B)  Ser180, Thr226, Glu228, Asp294  Null 
11(B)  Glu228, Glu277  Null 
12(B)  Asp151, Glu277, Asn325, Val346, Ser366  Null 
13(B)  Trp179, Asn295  Null 
14(A)  Asn295  Null 
15(B)  Arg152, Trp179, Asn295  Null 
16(B)  Glu119, Asp151, Ser366, Ser367, Tyr402  Ile223, Arg368 Int. J. Mol. Sci. 2012, 13  4500 
 
Table 1. Cont. 
Inhibitors   Hydrogen bonding–related residues   Non-bonding contact-related residues 
17(B)  Trp179  Null 
18(B)  Asp151, Arg152, Asn344  Null 
19(B)  Asp151, Trp179, Glu228, Asn295  Pro326 
20(B)  Arg152, Trp179, Ser247, Glu277  Null 
A: 2,3-dihydrobenzofuran backbone and B: 5,7-dihydroxychromen-4-one backbone. 
2.3. Flavonoid Derivatives Binding Free Energies 
The 2009 H1N1 neuraminidase/flavonoid (inhibitors 1–20) complex structures and the Tip3 water 
solvent box were constructed using the Autodock Vina docking and AmberTools 1.5 programs. The 
binding free energies of each inhibitor were obtained from the 10-ns MD simulation and the SIE 
method, with both processes using the same parameters. All the results are listed in Table 2. In the 
simulations, the predicted binding free energies of the 20 inhibitors was in good agreement with the 
experimental results (Figure 3), with the correlation coefficient being 0.75. 
Table  2.  Binding  free  energies  for  the  2009  H1N1  neuraminidase/flavonoid  
(inhibitors 1–20) complex structures by the SIE method. 
Inhibitors  Energy (kcal/mol) 
C E   vwd E   MSA   
R
bind G    bind G   (SIE)  bind G   (Experiment) 
1  −20.7  −9.95  6.12  −6.98  −6.825  −7.002 
2  −20.9  −7.36  5.29  −5.64  −6.435  −6.714 
3  −15.2  −6.69  4.83  −5.71  −5.771  −6.518 
4  −20.3  −5.31  5.31  −5.91  −6.186  −6.430 
5  −16.9  −6.12  5.81  −7.41  −6.071  −6.296 
6  −24.1  −7.26  6.43  −6.39  −6.837  −6.265 
7  −20.9  −7.36  5.11  −5.43  −6.413  −6.014 
8  −16.9  −4.81  6.57  −5.94  −5.779  −5.847 
9  −12.9  −4.64  5.11  −5.33  −5.277  −5.773 
10  −15.4  −4.73  5.59  −6.11  −5.633  −5.717 
11  −13.9  −4.91  6.19  −6.82  −5.567  −5.629 
12  −12.2  −6.71  3.91  −6.08  −5.503  −5.608 
13  −11.4  −5.73  4.41  −4.91  −5.193  −5.519 
14  −12.4  −5.12  5.25  −5.51  −5.291  −5.489 
15  −15.4  −4.73  5.65  −6.41  −5.766  −5.450 
16  −9.3  −8.73  6.81  −5.56  −5.353  −5.343 
17  −12.9  −4.32  4.81  −5.09  −5.221  −5.226 
18  −12.7  −4.21  4.61  −4.84  −5.163  −5.225 
19  −11.6  −4.29  4.82  −5.11  −5.084  −5.199 
20  −10.1  −4.33  4.99  −4.97  −4.916  −5.007 Int. J. Mol. Sci. 2012, 13  4501 
 
Figure 3. Predicted binding free energies versus experimentally determined binding free 
energies  of  the  20  inhibitors.  The  correlation  constant  (R
2)  is  equal  to  0.75.  The  
inhibitors 1–3 and 14 (red) belong to the 2,3-dihydrobenzofuran backbone inhibitors and 
the others belong to the 5,7-dihydroxychromen-4-one backbone inhibitors (black). 
 
2.4. Free Energies Contribution Analysis of Hydrophobic and Hydrophilic Nature of 20 Flavonoids 
The hydrophobic and hydrophilic nature of 20 flavonoids was individually traced down the binding 
affinities  with  the  important  residue  regions  analyzed  by  the  ligplot  program  (Arg152,  Asn295, 
Asn325, Asn344, Asp151, Asp295, Glu119, Glu228, Glu277, Ser180, Ser247, Ser366, Ser367, Thr226, 
Trp179, Tyr402), and the water molecules (within a 10 Å radius of 20 flavonoids). All the results are 
listed in Tables S2,3 and Figures S21,22. For the hydrophobic nature analysis (aromatic groups), the 
two residues (Trp179 and Tyr402) have obvious binding affinities to the inhibitors. The contributions  
to  Trp179  and  Tyr402  binding  free  energies  are  −1.121~−2.961  and  −1.665~−3.143  kcal/mol, 
respectively.  For  the  hydrophilic  nature  analysis,  the  three  elements  (side  chain  of  nitrogen 
atoms/Arg152, side chain of nitrogen and oxygen atoms/Asn295 and the water molecules within 10 Å 
of inhibitors) have obvious binding affinities to the inhibitors. Those contributions to Arg152, Asn295 
and water molecules binding free energies are −0.507~−2.733, −0.185~−2.247 and −0.6~−2.6 kcal/mol, 
respectively. Figure S23 shows that the more hydroxyl function groups are present, the higher the 
binding affinities of the inhibitors. 
3. Materials and Methods 
3.1. Molecular Docking 
All flavonoid derivatives inhibitors were constructed and minimized using  VEGA ZZ [41] and 
ISIS/DRAW [42] programs. We aligned the H1N1 neuraminidase structure (PBD ID: 3NSS) and the 
template (PDB ID: 3B7E) [43], and then used the template structure drug (zanamivir) as a template to 
generate  the  active  site  of  the  H1N1  neuraminidase  structure.  Next,  the  Autodock  vina  docking Int. J. Mol. Sci. 2012, 13  4502 
 
program [44] was used to dock the 20 flavonoid derivatives inhibitors into the active site of the H1N1 
neuraminidase structure, which was defined as all residues within 0.15 nm from alignment with the 
template structure drug. Autodock vina is a fast and accurate way to dock small compounds into fixed 
protein binding sites, utilizing NNscore [45] and several types of genetic algorithms. Four thousand 
conformations were obtained from docking for the 20 inhibitors, and these then scored by NNscore. 
The conformations of the best NNscores were then selected for subsequent MD simulations. 
3.2. Molecular Dynamics Simulation  
Calculations were performed with the NAMD molecular dynamics software [46] using the AMBER 
FF99 all-hydrogen amino acid and general amber force field (GAFF) parameters. The GAFF partial 
atomic charges are often based on the RESP fitting procedure of the electrostatic potential obtained at 
the HF/6–31G(d,p) level of theory [47]. Those levels of theory overestimate the gas-phase partial 
atomic charges giving rise to an effectively polarized force field. The geometries of the 20 flavonoid 
derivatives inhibitors were fully optimized and their electrostatic potentials were obtained using a 
single-point calculation; both operations were carried out at the HF level with the 6–31 G(d,p) basis set 
using  the  US  GAMESS  [48]  program.  Subsequently,  their  partial  charges  were  obtained  by  the 
restrained electrostatic potential (RESP) using R.E.D tools [49]. From the docking simulations, the 
complex structures were inserted into the tip3p water box. All MD simulations were performed in the 
NVT ensemble (temperature equal to 310 K), unless noted, using a Verlet integrator, an integration 
time step of 0.002 ps, and SHAKE [50] data for all covalent bonds involving hydrogen atoms. In 
electrostatic interactions, atom-based truncation was undertaken using the PME method. In addition, 
the switch van der Waals  functions  were also  used with  a 1.8 nm cutoff for atom-pair lists. The 
complex  structures  were  minimized  for  20,000  conjugate  gradient  steps.  The  minimized  complex 
structures  were  then  subjected  to  a  10  ns  isothermal,  constant  volume  MD  simulation.  The  MD 
simulation  trajectories  were  converted  to  the  Amber  type  coordinates  by  the  AmberTools  1.5 
program [51]. All MD simulation results were used to initiate the functionally important residues and 
the binding free energies calculations. 
3.3. Functionally Important Residues of H1N1 Influenza Neuraminidase 
In a diseased target proteins, not every residue is equally important. Some residues are essential for 
important  enzymatic  functions  and  protein  structure  stability.  Thus  identification  of  functionally 
important residues can provide a clear insight into the structural  aspects of  H1N1 2009 influenza 
neuraminidase.  In  this  work,  the  structure-based  approach  was  applied  to  identify  functionally 
important residues, while MD simulations were used to identify the residues involved in the binding 
pocket. In the MD simulations, the important residues regions were analyzed by the ligplot program [52]. The 
results of functional important residues were applied to binding free energies calculations. 
3.4. Binding Free Energies Calculations (Solvated Interaction Energies Method) 
The binding free energies calculations were performed by the solvated interaction energies method 
(SIE).  The  binding  free  energies  between  receptor  and  inhibitors  were  calculated  for  snapshot Int. J. Mol. Sci. 2012, 13  4503 
 
structures taken from the MD trajectory of the system. From the 10 ns protein-ligand MD trajectories, 
100 snapshots were taken at regular intervals for the binding energies analyses. The SIE function [53] 
to estimate the binding free energies is written as: 
C MSA E
D G D E C D G
vdw
in
R
bind in c in bind
   
    
)] (
) , ( ) ( [ ) , , , , (
 
    
  (1)  
where  C E  and  vdw E  are th e  inter molecular  Coulomb  and   van  der  Waals  inter act ion  ener g ies  in   the 
bound  sta te,  re spe ctivel y .  These   values   were   calc ulated  usin g   the   AM B E R  molecular  m echani cs  f orce 
field  (FF99)  with  an  opt imiz ed  dielectric  constant. 
R
bind G   is  the  change  in  the  re action  field  en er g ies 
between  the  bound  and  f re e  states  a nd  is  calculate d  b y   solvin g   the  Poisson  equation  with  the  boundar y  
element  method  pro g r am,  B R I   B EM,
 and using a molecular surface generated with a variable-radius 
solvent  probe.  The  ΔMSA  term  is  the  change  in  the  molecular  surface  area  upon  binding.  The 
following  parameters  are  calibrated  by  fitting  to  the  absolute  binding  free  energies  for  a  set  of  
protein–ligand  complexes:  AMBER  van  der  Waals  radii  linear  scaling  coefficient  (ρ),  the  solute 
interior dielectric constant (Din), the molecular surface area coefficient (γ), the global proportionality 
coefficient related to the loss of configurational entropy upon binding (α), and a constant (C). The 
optimized values of these parameters are α = 0.1048, Din = 2.25, ρ = 1.1, γ = 0.0129 kcal/(mol Å
2), 
and C = −2.89 kcal/mol. The SIE calculations were carried out with the program sietraj [53]. The 
hydrophobic (non-hydroxyl group) and hydrophilic (hydroxyl group) nature of flavonoids can affect 
the binding abilities [29–31]. Thus these natures were individually traced down to the binding affinities 
with the whole H1N1 neuraminidase, the important residue regions analyzed by the ligplot program 
(hydrophilic  and  hydrophobic  parts  listed  in  Table  S4),  and  the  water  molecules  (within  a  
10 Å radius of 20 flavonoids).  
4. Conclusions  
In this article, we used the Autodock vina program, tip3 water solvent model, MD simulations 
techniques, and the SIE method to predict the binding modes in which a series of flavonoid derivatives 
inhibitors interact with the 2009 H1N1 neuraminidase. From our simulations results, the correlation 
coefficient between the predicted binding free energies and experimental values of the 20 inhibitors is 
equal to 0.75. In the 2,3-dihydrobenzofuran backbone derivatives inhibitors (inhibitor 1–3 and 14), 
Asn295  forms  the hydrogen bonds  most frequently.  In the 5,7-dihydroxychromen-4-one backbone 
derivatives inhibitors (inhibitor 4–13 and 15–20), Glu228 forms the hydrogen bonds most frequently.  
The overall results of our simulations indicate that Arg152, Asn295, Asn325, Asn344, Asp151, 
Asp294,  Glu119,  Glu228,  Glu277,  Ser180,  Ser247,  Ser366,  Ser367,  Thr226,  Trp179,  Tyr402  and 
Val346 can form hydrogen bonds between the 2009 H1N1 neuraminidase and flavonoid derivatives. 
While  six  residues  (Arg152,  Asn295,  Glu228,  Glu277  Trp179  and  Val346)  more  often  form  the 
hydrogen bonds of the complex structures, Asn295 forms the hydrogen bonds most frequently. In the 
free energies contribution analysis, the two residues (the indole group of Trp179 and the benzene 
group  of  Tyr402)  have  obvious  binding  affinities  to  the  hydrophobic  nature  (aromatic-aromatic 
interactions)  of  the  20  inhibitors  ((2Z)-2-benzylidene-3H-benzofuran,  2-phenyl-4H-chromene  and 
benzene aromatic  groups), and the three elements  (the guanidine  group of Arg152, the acetamide Int. J. Mol. Sci. 2012, 13  4504 
 
group of Asn295 and the water molecules within 10 Å of inhibitors) have obvious binding affinities to 
the hydrophilic nature of the 20 inhibitors (–OH and =O groups). Figure S23 also shows that the more 
hydroxyl and oxygen function groups are present, the greater the number of binding affinities of the 
inhibitors.  Therefore,  our  approach  theoretically  suggests  that  the  four  residues  Arg152,  Trp179, 
Asn295 and Tyr402 are responsible for the selectivity of the flavonoid derivatives. 
Supporting Information 
The  2D  structures,  experimental  IC50  and  experimental  binding  free  energies  of  20  flavonoid 
derivatives are listed in Table S1. The functional residues analysis of the 20 flavonoid derivatives are 
listed  in  Figures  S1–S20.  Binding  free  energies  analysis  of  hydrophobic/hydrophilic  nature  of  20 
flavonoids are listed in Tables S2–S3 and Figures S21–S23.  
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